Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY26 results · Jan–Mar 2026
Panacea Biotec reported revenue from operations of ₹166.75 crore (up 25.8% from Q4 FY25) and net loss of ₹1.00 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 166.75 | 132.53 | +25.8% | 165.19 | +0.9% |
| Other income | 2.55 | 8.59 | −70.3% | 2.28 | +11.8% |
| Total income | 169.30 | 141.12 | +20.0% | 167.47 | +1.1% |
| Profit before tax | (1.25) | (0.04) | Loss widened | 6.49 | Turned loss |
| Net profit for the period | (1.00) | (1.99) | Loss narrowed | 3.89 | Turned loss |
| Attributable to shareholders of the company | 0.52 | (1.89) | Turned profit | 3.98 | −86.9% |
| EPS, basic (₹) | 0.08 | (0.31) | Turned profit | 0.65 | −87.7% |
| Net margin (%) | -0.6 | -1.5 | 2.4 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 111.12 | 67.90 | +63.7% | 99.31 | +11.9% |
| Other income | 5.60 | 6.09 | −8.0% | 3.84 | +45.8% |
| Total income | 116.72 | 73.99 | +57.8% | 103.15 | +13.2% |
| Profit before tax | (4.61) | (22.03) | Loss narrowed | (9.47) | Loss narrowed |
| Net profit for the period | (0.18) | (12.39) | Loss narrowed | (7.36) | Loss narrowed |
| EPS, basic (₹) | (0.03) | (2.02) | Loss narrowed | (1.20) | Loss narrowed |
| Net margin (%) | -0.2 | -18.2 | -7.4 |
Consolidated
- Filed with BSE
- 20 Aug 2026, 17:31 IST
- Board meeting
- 30 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Aug 2026, 17:31 IST
- Board meeting
- 30 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE